RNAZ – transcode therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its price target raised by analysts at HC Wainwright from $3.00 to $20.00. They now have a "buy" rating on the stock.
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial [Yahoo! Finance]
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split
TransCode Therapeutics, Inc. Announces $8 Million Private Placement [Yahoo! Finance]
Form 8-K Transcode Therapeutics, For: Dec 18
Form PRE 14A Transcode Therapeutics, For: Feb 28
Form EFFECT Transcode Therapeutics,
Form D Transcode Therapeutics,
Form S-1 Transcode Therapeutics,
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.